Yu.A. Shevchenko

Yu.A. Shevchenko

Auto-generated profile, based on publicly available information

Yu.A. Shevchenko

Research Institute of Fundamental and Clinical Immunology

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2015 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
EKEkaterina Vladimirovna Kulikova
Ekaterina Vladimirovna Kulikova
VKVasily Vasilevich Kurilin
Vasily Vasilevich Kurilin
JSJulia Aleksandrovna Shevchenko
Julia Aleksandrovna Shevchenko
IOIrina Aleksandrovna Obleukhova
Irina Aleksandrovna Obleukhova
EKEvgeny Aleksandrovich Khrapov
Evgeny Aleksandrovich Khrapov
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov
Significant effort has been devoted to developing effective cancer vaccines based on dendritic cells (DCs) loaded with various tumour antigens, including DNA constructs that carry sequences of tumour‐associated antigens (TAAs). Such vaccines efficiently and selectively activate the T cell immune response. In this study, we describe a method to induce an antitumour immune response in mononuclear cell (MNC) cultures from colorectal cancer patients using DNA‐transfected DCs encoding TAA epitopes of carcinoembryonic antigen, epithelial cell adhesion molecule and mucin 4. DCs were obtained from peripheral blood monocytes of colorectal cancer patients. Magnetic‐assisted transfection was used to deliver the genetic constructs to DCs. To assess the potency of the immune response, the antitumour cytotoxic response was assessed by lymphocyte intracellular perforin and the MNC cytotoxic activity against autologous tumour cells. We showed that polyepitope DNA‐transfected DCs enhanced MNC antitumour activity, increasing tumour cell death and the percentage of perforin‐positive lymphocytes. In addition, DNA‐transfected DCs elicited a cytotoxic response that was as efficient as that of tumour lysate‐loaded DCs. Taken together, the data suggest that it is feasible to induce an antitumour immune response in colorectal MNCs using transfected DCs. Thus, the DNA construct reported in this study may potentially be used in therapeutic and prophylactic DC‐based vaccines.

30 October 2022 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
YSYu. A. Shevchenko
Yu. A. Shevchenko
MKM. S. Kuznetsova
M. S. Kuznetsova
AKA. A. Khristin
A. A. Khristin
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov
The purpose of the study was to conduct a systematic literature review of high-technology methods in breast cancer treatment. Material and methods. To select information sources, a global search was used using the Web of Science, Scopus, PubMed, and RSCI databases. The search included the analysis of metadata by keywords, and relevant publications were used for full-text search. The review used 55 publications from 2001 to 2021. Most of the articles were published over the past 7 years. Results. Modern literature data presented in this review prove that long-term studies based on histological and immunological features of tumor development are very important for improving survival in breast cancer. Clinical treatment protocols that were based primarily on the anatomical characteristics of the disease are now switching to the biological mechanisms underlying carcinogenesis. Drugs targeting estrogen receptors play an important role in systemic therapy and make it possible to correct the mechanisms responsible for endocrine resistance. Targeted therapy targeting the HER2 receptor, especially in an antibody-drug conjugate combination, has associated cytotoxic therapy with anti-HER2 antibodies. Modern methods of biological therapy and cell engineering make it possible to develop methods for treating triple-negative breast cancer based on the regulation of the microenvironment, mechanisms of repair, immunosuppression, and the creation of a target from a larger repertoire of both surface and intracellular antigens. Conclusion. Promising strategies based on the use of signaling and metabolic pathways, cell surface molecules, and cell engineering increase the effectiveness of treatment and improve the progression-free and overall survival in breast cancer patients.

1 January 2022 in Immunologiya
Verified
Journal Article
Closed access
JPJu.G. Philippova
Ju.G. Philippova
MKM.S. Kuznetsova
M.S. Kuznetsova
YSYu.A. Shevchenko
Yu.A. Shevchenko
VTValeriy Tereshchenko
Valeriy Tereshchenko
MFMarina Fisher
Marina Fisher
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov
Фенотип и эффекторные функции GD2-специфичных CAR-T-клеток in vitro

1 January 2024 in Immunologiya
Verified
Journal Article
Open access
ABAleksey Bulygin
Aleksey Bulygin
JPJu.G. Philippova
Ju.G. Philippova
AAAlaa Alsalloum
Alaa Alsalloum
SASaleh Alrhmoun
Saleh Alrhmoun
FKF.D. Kireev
F.D. Kireev
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov
Оценка метаболизма TCR-подобных CAR/CAR/TCR-T-клеток в 3D-культуре

1 January 2024 in Immunologiya
Verified
Journal Article
Open access
JLJulia Lopatnikova
Julia Lopatnikova
YSYu.A. Shevchenko
Yu.A. Shevchenko
JFJu.G. Filippova
Ju.G. Filippova
MFMarina Fisher
Marina Fisher
IOIrina Obleukhova
Irina Obleukhova
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov
Технологии оценки антиген-специфических CD8+-лимфоцитов на основе мультимеров

1 January 2022 in Immunologiya
Verified
Journal Article
Closed access
RPRoman Yurievich Perik-Zavodskii
Roman Yurievich Perik-Zavodskii
YSYu.A. Shevchenko
Yu.A. Shevchenko
OKO.Yu. Koneva
O.Yu. Koneva
KNKirill Nazarov
Kirill Nazarov
MKM.S. Kuznetsova
M.S. Kuznetsova
SSSergey Vitalevich Sennikov
Sergey Vitalevich Sennikov